Tag: Trials

First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older

Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects at 9 trial sites across India

Jinu Jose, Vice President, Head – Sales and Clinical Operations, R&D Solutions, IQVIA India shared his views on the company's current operations, market scenario and future outlook

New guidelines have potential to transform the TB treatment landscape with six-month standard

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

It is time to prioritize the mental and physical wellbeing of those who every day are facing the worst of the pandemic on the frontlines

Considering the time and investment that go into developing a product or technology and for conducting field trials a science-based neutral approach is required...................

Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................

The second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.......................